Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of ...

A new analysis from the Paul Ehrlich Institute (PEI) and University Medical Center Freiburg, Freiburg, Germany, showed that only certain influenza A virus (IAV) strains trigger life-threatening ...

PVEK, a CD123-targeting antibody-drug conjugate, demonstrated strong response rates in two studies. Combined with VEN/AZA, it ...

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of ...

The triplet regimen of azacitidine, venetoclax, and tagraxofusp showed high complete response rates in both untreated and relapsed/refractory BPDCN patients. Safety profile of the triplet was ...

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in ...

An update from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.

ELZONRIS was approved by the FDA in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve ...

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN).BPDCN is a highly aggressive, orphan he ...

“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...